Redeye's short key take-away from Biovica's CMD that was completed recently is that Biovica is already aiming for larger opportunities outside the USD 600-1,000M opportunity in advanced breast cancer. For example, Biovica pointDiviTum is already pointing towards a USD 1bn to 1.5bn market for DiviTum in metastatic malignant melanoma (MMM), castration-resistant prostate cancer (CRPC) and non-small cell lung cancer (NSCLC).